Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

Calu-3 cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Angiotensin-converting Enzyme (ACE) (1) Apoptosis (2) Autophagy (3) Bacterial (1) CaSR (1) Cathepsin (2) CDK (1) Chloride Channel (1) Dihydroorotate Dehydrogenase (1) DNA/RNA Synthesis (2) EGFR (1) Elastase (1) Endogenous Metabolite (1) Fungal (1) Glutathione Peroxidase (1) HIV (1) IFNAR (2) Influenza Virus (1) Integrin (1) Keap1-Nrf2 (1) Necroptosis (1) NF-κB (2) Parasite (2) PKC (1) Potassium Channel (2) PROTACs (1) Reactive Oxygen Species (ROS) (1) Reference Standards (1) ROS Kinase (2) SARS-CoV (28) Ser/Thr Protease (3) STING (1) Virus Protease (1)
By Research Areas:	Cancer (7) Cardiovascular Disease (3) Endocrinology (1) Infection (32) Inflammation/Immunology (5) Metabolic Disease (4) Neurological Disease (1)

By Targets:

Angiotensin-converting Enzyme (ACE) (1)

Apoptosis (2)

Autophagy (3)

Bacterial (1)

CaSR (1)

Cathepsin (2)

CDK (1)

Chloride Channel (1)

Dihydroorotate Dehydrogenase (1)

DNA/RNA Synthesis (2)

EGFR (1)

Elastase (1)

Endogenous Metabolite (1)

Fungal (1)

Glutathione Peroxidase (1)

HIV (1)

IFNAR (2)

Influenza Virus (1)

Integrin (1)

Keap1-Nrf2 (1)

Necroptosis (1)

NF-κB (2)

Parasite (2)

PKC (1)

Potassium Channel (2)

PROTACs (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (1)

ROS Kinase (2)

SARS-CoV (28)

Ser/Thr Protease (3)

STING (1)

Virus Protease (1)

By Research Areas:

Cancer (7)

Cardiovascular Disease (3)

Endocrinology (1)

Infection (32)

Inflammation/Immunology (5)

Metabolic Disease (4)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Targets Recommended: Nuclear Factor of activated T Cells (NFAT) TREM receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14909

Bardoxolone Maximum Cited Publications 23 Publications Verification CDDO; RTA 401	Keap1-Nrf2 NF-κB SARS-CoV Apoptosis Reactive Oxygen Species (ROS) Glutathione Peroxidase Necroptosis	Infection Neurological Disease Inflammation/Immunology Cancer
Bardoxolone (CDDO; RTA 401) is a Nrf2 activator. Bardoxolone shows anti-SARS-CoV-2 3CLpro with IC50 of 27.99 μM. Bardoxolone activates the Nrf2 pathway and inhibits the NF-κB pathway. Bardoxolone can induce cells differentiation, apoptosis and shows antiproliferative activity against cancer cells. Bardoxolone can increase ROS and decrease intracellular GSH levels. Bardoxolone inhibits Z-VAD-FMK (HY-16658B)-induced necroptosis. Bardoxolone can be used for the research of cancer, inflammation and infection, such as SARS-CoV infection and glioblastoma .

HY-17437

Mefloquine 4 Publications Verification Mefloquin	Parasite Autophagy SARS-CoV Potassium Channel ROS Kinase	Infection Metabolic Disease Inflammation/Immunology Cancer
Mefloquine (Mefloquin), an orally active and potent quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine is also a K ⁺ channel (KvQT1/minK) antagonist with an IC₅₀ of ~1 μM. Mefloquine can be used for malaria, systemic lupus erythematosus and cancer research .

HY-15275

BMS-265246 2 Publications Verification	CDK Angiotensin-converting Enzyme (ACE)	Infection Cardiovascular Disease Cancer
BMS-265246 is a potent and selective cyclin-dependent kinase CDK1 and CDK2 inhibitor, with IC₅₀ values of 6 and 9 nM, respectively. BMS-265246 inhibits CHI3L1 (chitinase 3-like-1) stimulation of ACE2 (angiotensin converting enzyme 2) and SPP (viral spike protein priming proteases). BMS-265246 can be used for ovarian cancer and COVID-19 research .

HY-168034

diABZI-4	STING Integrin NF-κB SARS-CoV	Infection Inflammation/Immunology
diABZI-4 is a STING activator and broad-spectrum antiviral agent with immunostimulatory activity. diABZI-4 triggers the TBK1-IRF3 and NF-κB signaling cascades by inducing STING oligomerization, thereby promoting the production of type I/III interferons and various proinflammatory cytokines. diABZI-4 exhibits broad-spectrum antiviral activity and effectively inhibits the replication of influenza A virus, SARS-CoV-2, herpes simplex virus, and other viruses. diABZI-4 also activates lymphocytes and macrophages to provide significant pre- and post-exposure protection in viral disease models. diABZI-4 can be used to study COVID-19, respiratory viral infections, and related immunopathological mechanisms .

HY-132191

Pradimicin A	Fungal SARS-CoV HIV	Infection
Pradimicin A is a potent antifungal agent with a minimum inhibitory concentration (MIC) of 4 μg/mL against Candida rugosa. Pradimicin A exhibits antiviral activity against SARS-CoV, human immunodeficiency virus (HIV) and other enveloped viruses. Pradimicin A exerts its fungicidal activity through a Ca ²⁺-dependent mechanism, which induces fungal lysis. Pradimicin A can be used in research related to fungal infections, HIV infections and COVID-19 .

HY-137978

Ezurpimtrostat 3 Publications Verification GNS561	SARS-CoV IFNAR Autophagy Apoptosis	Infection Metabolic Disease Inflammation/Immunology Cancer
Ezurpimtrostat (GNS561) is an orally active PPT1 inhibitor, autophagy inhibitor, immunomodulator, anti-inflammatory agent, and anticancer agent. Ezurpimtrostat inhibits PPT1, dysregulates lysosomal function, redistributes mTOR, and induces apoptosis. Ezurpimtrostat reduces IFN‑α, CRP, immune complex deposition, and SARS‑CoV‑2 viral load. Ezurpimtrostat can be used for the study of systemic lupus erythematosus, SARS‑CoV‑2, hepatocellular carcinoma, fibrosis, and related disorders .

HY-158405

PAV-104	SARS-CoV	Infection
PAV-104 inhibits SARS-CoV-2 replication, with the MOI of 0.01. PAV-104 can interact with SARS-CoV-2 nucleocapsid (N) and interfered with its oligomerization, blocking particle assembly .

HY-W195509

Debrisoquin hydroiodide Debrisoquine hydroiodide; Isocaramidine hydroiodide; Ro 5-3307/1 hydroiodide	SARS-CoV Ser/Thr Protease	Infection
Debrisoquin (hydroiodide) is the hydrochloride form of Debrisoquin (HY-B1624). Debrisoquin is a TMPRSS2 inhibitors that inhibits SARS-CoV-2 entry into human lung cell line by a TMPRSS2-depedent manner. Debrisoquin can be used for antiviral research .

HY-B1624A

Debrisoquin hemisulfate Debrisoquine hemisulfate; Isocaramidine hemisulfate; Ro 5-3307/1 hemisulfate	Endogenous Metabolite	Infection Cardiovascular Disease
Debrisoquin (Isocaramidine) hemisulfate is a TMPRSS2 inhibitors that inhibits SARS-CoV-2 entry into human lung cell line by a TMPRSS2-depedent manner, with an IC₅₀ of 22μM. Debrisoquin hemisulfate can be used for antiviral research .

HY-177303

AXT-914	CaSR SARS-CoV	Infection Metabolic Disease Endocrinology
AXT-914 is a Calcium-sensing receptor (CaSR) inhibitor. AXT-914 has antiviral activity against the coronavirus HCoV 229E and SARS-CoV2. AXT914 reduces cytosolic calcium signalling activity of CaSR mutations. AXT-914 can be used for Bartter syndrome type 5 and autosomal dominant hypocalcemia (ADH) and coronavirus infections research .

HY-B1624

Debrisoquin Debrisoquine; Isocaramidine; Ro 5-3307/1	SARS-CoV Ser/Thr Protease	Infection Cardiovascular Disease
Debrisoquin (Isocaramidine) is a TMPRSS2 inhibitors that inhibits SARS-CoV-2 entry into human lung cell line by a TMPRSS2-depedent manner, with an IC₅₀ of 22μM. Debrisoquin can be used for antiviral research .

HY-163206

SARS-CoV-2-IN-77	Cathepsin SARS-CoV	Infection
SARS-CoV-2-IN-77 (compound 11e) is a cathepsin L and cathepsin S inhibitor with K_i values of 111 nM and 103 nM, respectively. SARS-CoV-2-IN-77 inhibits SARS-CoV-2 with an EC₅₀ value of 38.4 nM in Calu-3 cells without showing cytotoxicity .

HY-155016

SARS-CoV-2-IN-46	SARS-CoV	Infection
SARS-CoV-2-IN-46 is a novel coronavirus (SARS-CoV-2) replication inhibitor with an EC₅₀ of 0.9 μM in Calu-3 cells. SARS-CoV-2-IN-46 has antiviral activity and can be used in novel coronavirus (COVID-19) research .

HY-155014

SARS-CoV-2-IN-44	SARS-CoV	Infection
SARS-CoV-2-IN-44, a inhibitor of SARS-CoV-2, inhibits viral replication, with an EC₅₀ of 0.6μM. SARS-CoV-2-IN-44 has no evident cytotoxic effect in Calu-3 cells and can be used for antiviral research .

HY-176280

SARS-CoV-2-IN-115	SARS-CoV Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Infection
SARS-CoV-2-IN-115 (Compound 3e) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-115 has potent antiviral activity against SARS-CoV-2 in infected Calu-3 cells (EC₅₀: 1.7  μM). SARS-CoV-2-IN-115 effectively inhibits the activity of human dihydroorotate dehydrogenase (HsDHODH) (IC₅₀: 1.5  μM). SARS-CoV-2-IN-115 preserves immune response without antiproliferative effects on CD4 T cells .

HY-155015

SARS-CoV-2-IN-45	SARS-CoV	Infection
SARS-CoV-2-IN-45 (Compound 8p) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-45 inhibits SARS-CoV-2 replication in Calu-3 cell with an EC₅₀ of 0.5 μM, and has no evident cytotoxic effect .

HY-17437R

Mefloquine (Standard) Mefloquin (Standard)	Parasite Autophagy SARS-CoV Potassium Channel ROS Kinase Reference Standards	Infection Metabolic Disease Inflammation/Immunology Cancer
Mefloquine (Standard) is the analytical standard of Mefloquine. This product is intended for research and analytical applications. Mefloquine (Mefloquin), an orally active and potent quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine is also a K+ channel (KvQT1/minK) antagonist with an IC50 of ~1 μM. Mefloquine can be used for malaria, systemic lupus erythematosus and cancer research .

HY-156325

SARS-CoV-2-IN-62	SARS-CoV	Infection
SARS-CoV-2-IN-62 (Compound R3b) is an inhibitor of SARS-CoV-2 replication and has low cytotoxicity. SARS-CoV-2-IN-62 inhibits viral replication in Vero E6 cells and Calu-3 cells, with EC₅₀ values of 2.97 μM and 3.82 μM, respectively .

HY-156337

SARS-CoV-2-IN-63	SARS-CoV	Infection
SARS-CoV-2-IN-63 (Compound R3e) is an inhibitor of SARS-CoV-2 replication and has low cytotoxicity. SARS-CoV-2-IN-63 inhibits viral replication in Vero E6 cells and Calu-3 cells, with EC₅₀ values of 1.99 μM and 1.92 μM, respectively .

HY-173459

N-0920	SARS-CoV	Infection
N-0920 is a potent TMPRSS2 inhibitor with an IC₅₀ of 0.35 nM. N-0920 effectively inhibits SARS-CoV-2 variants EG.5.1 and JN.1 entry in Calu-3 cells, with picomolar EC₅₀s values of 300 pM and 90 pM, respectively .

HY-163029

CTSL/B-IN-1	Cathepsin SARS-CoV	Infection
CTSLCTSB-IN-1 (compound 212-148) is a bispecific inhibitor of host viral spike cleaver proteins CTSL/CTSB and TMPRSS2 with IC₅₀s of 2.13/64.07 nM and 1.38 μM, respectively. CTSLCTSB-IN-1 blocks two relevant SARS-CoV-2 viral entry pathways by inhibiting the viral spike cleavage and can be applied to anti-SARS-CoV-2 research .

HY-156441

SARS-CoV-2-IN-65	SARS-CoV	Infection
SARS-CoV-2-IN-65 (compound 2f (81)) is a potent,orally active and reversible SARS-CoV-2 entry inhibitor. SARS-CoV-2-IN-65 inhibits the pseudovirus entry in a ACE2-dependent pathway, via mainly inhibiting RBD:ACE2 interaction and TMPRSS2 activity in Calu-3 cells .

HY-168917

9-Aminominocycline 9-AMN	SARS-CoV Virus Protease	Infection
9-Aminominocycline (9-AMN) is the inhibitor for SARS-CoV-2 papain-like protease (SARS-CoV-2 PLpro), inhibits its deubiquitination (DUB) activity and protease activity with IC₅₀ of 4.55 µM and 4.15 µM. 9-Aminominocycline inhibits the SARS-CoV variants Delta and Omicron replication in Calu-3 cell with IC₅₀ of 1.04 µM and 2.35 µM .

HY-162719

RH12	DNA/RNA Synthesis SARS-CoV	Infection
RH12 is a dual inhibitor for SARS-CoV-2 related RNA-dependent RNA polymerase (RdRp, IC₅₀ is 4.42 nM) and human transmembrane serine protease 2 (TMPRSS2, IC₅₀ is 4.2 nM). RH12 exhibits antiviral efficacy. RH12 inhibits viral replication and absorption, and exhibits a 90.5% virucidal effects on Vero-E6 cells. RH12 inhibits cell viability of Calu-3 with an IC₅₀ of 17.5 nM .

HY-P991233

BAT1006	EGFR	Cancer
BAT1006 is a monoclonal antibody targeting HER2 extracellular domain II with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) for the study of HER2-positive locally advanced/metastatic solid tumors. BAT1006 has an approximately 5-fold enhanced ADCC effect compared to pertuzumab (HY-P9912) and exhibits potent anti-tumor activity in the HER2-positive Calu-3 xenograft mouse model .

HY-149304

SARS-CoV-2-IN-40	SARS-CoV	Infection
SARS-CoV-2-IN-40 (Compound 19) is a SARS-CoV-2 inhibitor. SARS-CoV-2-IN-40 inhibits SARS-CoV-2 BA.1 and BA.5 variant infection of Calu3 lung cells, with IC₅₀s of 100 nM and 160 nM respectively .

HY-157805

PROTAC SARS-CoV-2 Mpro degrader-2	PROTACs SARS-CoV	Infection
PROTAC SARS-CoV-2 Mpro degrader-2 (Compound 6) is a potent PROTAC degrader of SARS-CoV-2 M ^pro. PROTAC SARS-CoV-2 Mpro degrader-2 has broad-spectrum antiviral activity against CoVs, including SARS-CoV-2 (EC₅₀ = 10.8 μM), HCoV-OC43 (EC₅₀ = 1.6 μM) and HCoV-229E (EC₅₀ = 6.5 μM). PROTAC SARS-CoV-2 Mpro degrader-2 exhibits potent activity against SARS-CoV-2 in Calu-3 cells, with an EC₅₀ of 0.89 μM .

HY-162492

Influenza A virus-IN-14	Influenza Virus	Infection
Influenza A virus-IN-14 (Compound 37) is an inhibitor for influenza virus type A (IAV), which inhibits H1N1 with an EC₅₀ of 23 nM. Influenza A virus-IN-14 exhibits low cytotoxicity with CC₅₀ of more than 100 μM. Influenza A virus-IN-14 inhibits cytopathic effect and improves the survival rates of cell Calu3. Influenza A virus-IN-14 exhibits synergistic activity with the neuraminidase inhibitor Oseltamivir (HY-13317). Influenza A virus-IN-14 exhibits poor pharmacokinetic properties in CD-1 mouse .

HY-176453

Allobetulone N066-0059	Chloride Channel	Cancer
Allobetulone (N066-0059) is a TMEM16A inhibitor (IC₅₀: 0.24 µM). Allobetulone (N066-0059) can be used in anti-cancer research .

HY-B1624C

Debrisoquin hydrobromide Debrisoquine hydrobromide; Isocaramidine hydrobromide; Ro 5-3307/1 hydrobromide	SARS-CoV Ser/Thr Protease	Infection
Debrisoquine (Ro 5-3307/1) hydrobromide is a TMPRSS2 inhibitors that inhibits SARS-CoV-2 entry into human lung cell line by a TMPRSS2-depedent manner, with an IC₅₀ of 22μM. Debrisoquine hydrobromide can be used for antiviral research .

HY-170894

SARS-CoV-2 Mpro-IN-37	SARS-CoV	Infection
SARS-CoV-2 Mpro-IN-37 (compound 8r) is a SARS-CoV-2 main protease (M ^pro) inhibitor, with an IC₅₀ of 0.0199 μM. SARS-CoV-2 Mpro-IN-37 inhibits SARS-CoV-1 M ^pro and MERS-CoV M ^pro with IC₅₀s of 0.00945 and 0.111 μM, respectively. SARS-CoV-2 Mpro-IN-37 displays high antiviral activity in the nanomolar range without showing cellular toxicity .

HY-181165

SB2960	PKC SARS-CoV IFNAR	Infection
SB2960 is a receptor for activated protein C kinase 1 (RACK1) binder with a human K_D of 5.65 μM. SB2960 can promote stress granule (SG) formation and exhibit potent antiviral activity across diverse viral species. SB2960 suppresses viral replication with minimal cytotoxicity by modulating host antiviral immune responses. SB2960 increases the thermal stability of RACK1 and reduces SARS-CoV-2 N protein levels. SB2960 enhances type I interferon (IFN-β) expression and inhibits RIG-I, ISG56, and RANTES expression. SB2960 can be used for the research of virus infection .

HY-181647

LasB-IN-3	Bacterial Elastase	Infection
LasB-IN-3 is a protease elastase (LasB) inhibitor of Pseudomonas aeruginosa with an IC₅₀ value of 8.5 nM. LasB-IN-3 shows an IC₅₀ of 58.9 nM for the Met128Val mutant. LasB-IN-3 binds to active sites of wild-type and Met128Val mutant LasB, coordinates zinc ions, forms hydrogen bonds and CH-π interactions, and inhibits LasB proteolytic activity. LasB-IN-3 increases survival rate in LasB-induced acute lung injury mice models. LasB-IN-3 can be used for the research of Pseudomonas aeruginosa infection .

HY-182913

SARS-CoV-2-IN-122	SARS-CoV	Infection
SARS-CoV-2-IN-122 is a SARS-CoV-2 inhibitor by targeting the S2 subunit of the spike protein. SARS-CoV-2-IN-122 interacts with residues linked to membrane fusion-associated conformational rearrangements, interfering with viral entry events. SARS-CoV-2-IN-122 inhibits SARS-CoV-2 replication, lacks direct virucidal activity, and does not impair viral-host cell attachment. SARS-CoV-2-IN-122 exhibits activity against SARS-CoV-2 variants including B.1 and Omicron (BA.2.86.1). SARS-CoV-2-IN-122 can be used for the research of coronavirus disease 2019 (COVID-19) .

Cat. No.	Product Name	Target	Research Area

HY-173459

N-0920	SARS-CoV	Infection
N-0920 is a potent TMPRSS2 inhibitor with an IC₅₀ of 0.35 nM. N-0920 effectively inhibits SARS-CoV-2 variants EG.5.1 and JN.1 entry in Calu-3 cells, with picomolar EC₅₀s values of 300 pM and 90 pM, respectively .

Cat. No.	Product Name	Target	Research Area	Image

HY-P991233

BAT1006	EGFR	Cancer
BAT1006 is a monoclonal antibody targeting HER2 extracellular domain II with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) for the study of HER2-positive locally advanced/metastatic solid tumors. BAT1006 has an approximately 5-fold enhanced ADCC effect compared to pertuzumab (HY-P9912) and exhibits potent anti-tumor activity in the HER2-positive Calu-3 xenograft mouse model .

Debrisoquin hemisulfate Debrisoquine hemisulfate; Isocaramidine hemisulfate; Ro 5-3307/1 hemisulfate	Infection Alkaloids Classification of Application Fields Endogenous metabolite Isoquinoline Alkaloids Disease Research Fields Source Classification	Endogenous Metabolite
Debrisoquin (Isocaramidine) hemisulfate is a TMPRSS2 inhibitors that inhibits SARS-CoV-2 entry into human lung cell line by a TMPRSS2-depedent manner, with an IC₅₀ of 22μM. Debrisoquin hemisulfate can be used for antiviral research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks